Gal-3 has long been known to be a mediator of fibrosis in multiple organs including the kidney (6) .
The absence of a cardiac contribution to systemic levels of Gal-3 has been recognized in patients supported by a ventricular assist device, where the amount of Gal-3 in the extracted myocardial tissue correlates poorly with the systemic levels (7).
In patients with chronic heart failure with reduced ejection fraction (HFrEF) undergoing biventricular pacemaker implantation, coronary sinus levels were actually found to be lower than systemic levels of Gal-3, suggesting the negligible contribution of cardiac sources to systemic levels (8) . Recently, there has been more insight into cardiac-renal interaction with Gal-3. First, Meijers et al. (9) showed that despite sera levels of Gal-3 that were higher in HF patients than in controls, urine levels were similar, demonstrating that HF patients had a lower fractional renal extraction than controls, explaining one possible cause of elevated levels in patients with HF. Second, aldosterone-salt-treated rats showed both increased cardiac and renal expression levels of Gal-3 mRNA and protein, as well as protein synthesis of collagen type I and histologic evidence of fibrosis in both organs. Cotreatment with spironolactone prevented these changes, as did modified citrus pectin, a Gal-3-specific inhibitor (10) . Clinical support for a strong association between renal function and Gal-3 has been shown in predominantly chronic HFrEF and general population cohorts (11) (12) (13) . The association of Gal-3 levels and risk of new-onset HF no longer achieved statistical significance after accounting for patients with prevalent chronic kidney disease (CKD) in the Framingham Heart Study (14) . However, in that same cohort, higher levels of Gal-3 were predictive of incident CKD even in extensively adjusted models, suggesting that Gal-3 might perform better as a marker for the progression of renal rather than cardiac disease in general population cohorts (15) . In contrast to the RELAX substudy, the Aldo-DHF study showed that even after adjustment for renal function, Gal-3 levels were significantly inversely associated with 6-min walk distance and almost remained associated with peak VO 2. In Aldo-DHF, there was no significant interaction between spironolactone and Gal-3 levels, and baseline levels did not predict all-cause mortality and hospitalization deFilippi and Christenson Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a
